Figure 2. Kaplan-Meier curves of overall survival of patients with head and neck squamous cell carcinoma who received nivolumab therapy. Overall survival (OS) curves according to performance status (PS) (A), site of recurrence (B), platinum-refractory status (C) and occurrence of immunerelated adverse events (irAEs) (D). m: Months.